286 related articles for article (PubMed ID: 26829357)
1. The role of biomarkers and imaging in Parkinson's disease.
Algarni MA; Stoessl AJ
Expert Rev Neurother; 2016; 16(2):187-203. PubMed ID: 26829357
[TBL] [Abstract][Full Text] [Related]
2. Problems associated with fluid biomarkers for Parkinson's disease.
Nyhlén J; Constantinescu R; Zetterberg H
Biomark Med; 2010 Oct; 4(5):671-81. PubMed ID: 20945980
[TBL] [Abstract][Full Text] [Related]
3. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
[TBL] [Abstract][Full Text] [Related]
4. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
5. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.
Farotti L; Paciotti S; Tasegian A; Eusebi P; Parnetti L
Expert Rev Mol Diagn; 2017 Aug; 17(8):771-780. PubMed ID: 28604235
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.
Shi M; Bradner J; Hancock AM; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Kim HM; Leverenz JB; Montine TJ; Ginghina C; Kang UJ; Cain KC; Wang Y; Aasly J; Goldstein D; Zhang J
Ann Neurol; 2011 Mar; 69(3):570-80. PubMed ID: 21400565
[TBL] [Abstract][Full Text] [Related]
7. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
8. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
[TBL] [Abstract][Full Text] [Related]
9. [Proteomic biomarkers in Parkinson's disease].
Bandrés S; Durán R; Barrero F; Ramírez M; Vives F
Rev Neurol; 2014 Feb; 58(4):166-74. PubMed ID: 24504879
[TBL] [Abstract][Full Text] [Related]
10. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
[TBL] [Abstract][Full Text] [Related]
11. CSF α-synuclein, tau, and amyloid β in Parkinson's disease.
Shi M; Zhang J
Lancet Neurol; 2011 Aug; 10(8):681; author's reply 681-3. PubMed ID: 21777821
[No Abstract] [Full Text] [Related]
12. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for trials of neuroprotection in Parkinson's disease.
Agarwal PA; Stoessl AJ
Mov Disord; 2013 Jan; 28(1):71-85. PubMed ID: 22927101
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
15. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
16. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
18. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
19. Biochemical premotor biomarkers for Parkinson's disease.
Mollenhauer B; Zhang J
Mov Disord; 2012 Apr; 27(5):644-50. PubMed ID: 22508282
[TBL] [Abstract][Full Text] [Related]
20. CSF biomarkers and clinical progression of Parkinson disease.
Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
